Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDA Orange Book
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Drugs in Development
Details:
Citius intends to use proceeds for the pre-clinical and clinical development of Lymphir (denileukin diftitox), a recombinant fusion protein combining interleukin-2 and diphtheria toxin.
Lead Product(s): Denileukin Diftitox,Tisagenlecleucel
Therapeutic Area: Oncology Brand Name: Lymphir
Study Phase: Phase IProduct Type: Large molecule
Sponsor: H.C. Wainwright & Co
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 26, 2024
Lead Product(s) : Denileukin Diftitox,Tisagenlecleucel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $15.0 million
Deal Type : Private Placement
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
Details : Citius intends to use proceeds for the pre-clinical and clinical development of Lymphir (denileukin diftitox), a recombinant fusion protein combining interleukin-2 and diphtheria toxin.
Brand Name : Lymphir
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 26, 2024
Details:
Lymphir™ (denileukin diftitox) in combination with FDA-approved CAR-T products like tisagenlecleucel or lisocabtagene maraleucel is being investigated for relapsed or refractory B-cell lymphomas.
Lead Product(s): Denileukin Diftitox,Tisagenlecleucel
Therapeutic Area: Oncology Brand Name: Lymphir
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Lead Product(s) : Denileukin Diftitox,Tisagenlecleucel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Citius Adds City of Hope to UMN’s LYMPHIR Phase 1 for B-Cell Lymphoma
Details : Lymphir™ (denileukin diftitox) in combination with FDA-approved CAR-T products like tisagenlecleucel or lisocabtagene maraleucel is being investigated for relapsed or refractory B-cell lymphomas.
Brand Name : Lymphir
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 11, 2024
Details:
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit.
Lead Product(s): Efineptakin Alfa,Tisagenlecleucel
Therapeutic Area: Oncology Brand Name: NT-I7
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2022
Lead Product(s) : Efineptakin Alfa,Tisagenlecleucel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit.
Brand Name : NT-I7
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 04, 2022
Details:
44% of patients who experienced remission within three months of infusion were still in remission at the five-year mark, demonstrating the long-term benefit and curative potential of one-time Kymriah (Tisagenlecleucel) infusion.
Lead Product(s): Tisagenlecleucel
Therapeutic Area: Oncology Brand Name: Kymriah
Study Phase: ApprovedProduct Type: Cell and Gene therapy
Sponsor: Perelman School of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2022
Lead Product(s) : Tisagenlecleucel
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Perelman School of Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis Five-year Kymriah® Data Show Durable Remission and Long-term Survival Maintained in Chil...
Details : 44% of patients who experienced remission within three months of infusion were still in remission at the five-year mark, demonstrating the long-term benefit and curative potential of one-time Kymriah (Tisagenlecleucel) infusion.
Brand Name : Kymriah
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 12, 2022
Details:
The approval of Kymriah (Tisagenlecleucel) is based on data from the Phase II ELARA trial, a single-arm, open-label trial, in which 90 patients were evaluated for efficacy with a median follow-up of approximately 17 months.
Lead Product(s): Tisagenlecleucel
Therapeutic Area: Oncology Brand Name: Kymriah
Study Phase: ApprovedProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Lead Product(s) : Tisagenlecleucel
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Novartis Kymriah® CAR-T Cell Therapy for Adult Patients With Relapsed or Refractory ...
Details : The approval of Kymriah (Tisagenlecleucel) is based on data from the Phase II ELARA trial, a single-arm, open-label trial, in which 90 patients were evaluated for efficacy with a median follow-up of approximately 17 months.
Brand Name : Kymriah
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 27, 2022
Details:
Approval based on the Phase II ELARA trial showing Kymriah (tisagenlecleucel) demonstrated high response rates in heavily pretreated patients, including an 86% overall response rate and a 69% complete response.
Lead Product(s): Tisagenlecleucel
Therapeutic Area: Oncology Brand Name: Kymriah
Study Phase: ApprovedProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Lead Product(s) : Tisagenlecleucel
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis Kymriah® Receives EC Approval as First Car-t Cell Therapy for Adults With Relapsed or Re...
Details : Approval based on the Phase II ELARA trial showing Kymriah (tisagenlecleucel) demonstrated high response rates in heavily pretreated patients, including an 86% overall response rate and a 69% complete response.
Brand Name : Kymriah
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 04, 2022
Details:
CHMP opinion based on Phase II global ELARA trial for Kymriah, demonstrating high response rates in heavily pretreated patients; 69% experienced a complete response, with an 86% overall response rate and a remarkable safety profile.
Lead Product(s): Tisagenlecleucel
Therapeutic Area: Oncology Brand Name: Kymriah
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022
Lead Product(s) : Tisagenlecleucel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis Receives Positive CHMP Opinion For Kymriah® CAR-T Cell Therapy for Adult Patients with R...
Details : CHMP opinion based on Phase II global ELARA trial for Kymriah, demonstrating high response rates in heavily pretreated patients; 69% experienced a complete response, with an 86% overall response rate and a remarkable safety profile.
Brand Name : Kymriah
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 25, 2022
Details:
CAR T-cell therapy tisagenlecleucel (tisa-cel) was not found to improve event-free survival over what was seen with standard of care as a second-line treatment for patients with aggressive non-Hodgkin lymphoma.
Lead Product(s): Tisagenlecleucel
Therapeutic Area: Oncology Brand Name: Kymriah
Study Phase: ApprovedProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
Lead Product(s) : Tisagenlecleucel
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CAR T-cell therapy tisagenlecleucel (tisa-cel) was not found to improve event-free survival over what was seen with standard of care as a second-line treatment for patients with aggressive non-Hodgkin lymphoma.
Brand Name : Kymriah
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 14, 2021
Details:
Under the terms of the agreement, Oxford Biomedica will receive payments related to the development and manufacturing of lentiviral vectors for use in clinical trials with also allowing for payments for the manufacture and supply of lentiviral vectors for commercial use.
Lead Product(s): Tisagenlecleucel
Therapeutic Area: Oncology Brand Name: Kymriah
Study Phase: ApprovedProduct Type: Cell and Gene therapy
Sponsor: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 13, 2021
Lead Product(s) : Tisagenlecleucel
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Oxford Biomedica In License and Supply Deals With Novartis and Arcellx
Details : Under the terms of the agreement, Oxford Biomedica will receive payments related to the development and manufacturing of lentiviral vectors for use in clinical trials with also allowing for payments for the manufacture and supply of lentiviral vectors fo...
Brand Name : Kymriah
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 13, 2021
Details:
Kymriah (tisagenlecleucel) is an autologous, immunocellular cancer therapy which involves reprogramming a patient's T-cells with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing cells. It is administered as intravenous infusion.
Lead Product(s): Tisagenlecleucel
Therapeutic Area: Oncology Brand Name: Kymriah
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2021
Lead Product(s) : Tisagenlecleucel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis Receives Priority Review by US FDA and Filing Acceptance By EMA for Kymriah® To Treat Pa...
Details : Kymriah (tisagenlecleucel) is an autologous, immunocellular cancer therapy which involves reprogramming a patient's T-cells with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing cells. It is administered as...
Brand Name : Kymriah
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Finished Drug Prices
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Annual Reports
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 474
2019 Revenue in Millions : 278
Growth (%) : 71
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 587
2020 Revenue in Millions : 474
Growth (%) : 24
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 536
2021 Revenue in Millions : 587
Growth (%) : -9
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 508
2022 Revenue in Millions : 536
Growth (%) : -5
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 76
2017 Revenue in Millions : 6
Growth (%) : 1167%
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 278
2018 Revenue in Millions : 76
Growth (%) : 266
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
